ACS Biomed builds strategic collaborations across consumer health, pharmaceutical development and healthcare innovation. Each opportunity is assessed according to the maturity of the relevant asset, commercial feasibility, scientific documentation and applicable regulatory requirements.
Eligible opportunities may include ErpeCream / E-Cream, ErpeLips / E-Lip, ARTROFLEX and DENTAL-BIO, subject to product status, territory and applicable market requirements. Discussions can cover territorial distribution, product evaluation and commercial supply arrangements.
The ErpeCream Investigational Pharmaceutical Development Programme is separate from cosmetic product commercialization. ACS Biomed welcomes qualified discussions around scientific evaluation, pharmaceutical development, licensing, co-development and potential territorial or strategic agreements. No approved medicine is presented here.
Selected opportunities may involve formulation development, technology transfer, industrial partnerships, manufacturing and supply-chain development. Specific projects, budgets and negotiations remain confidential until appropriately authorized.